OAKLAND, CA–(Marketwire – October 12, 2010) –  It took vision, years of planning and advocacy; a true labor of love. On Thursday, October 7 Alameda’s newest partner for family members dealing with their own very personal journeys — The Family Education and Resource Center (FERC) (www.askferc.org) — celebrated one year of “being there” for residents of Alameda County. More importantly, the event, called “Partners In This Journey,” celebrated those who worked tirelessly for years setting the stage for this program to finally be funded with Mental health Services Act funds. The event took place at Oakland’s Waterfront Hotel and coincided with National Mental Illness Awareness Week (October 3 – 9, 2010).

“We wanted to thank everyone who participated in the visioning, creation and existence of FERC (www.askferc.org).”

“We’ve been there; we can help,” says Karina Foote, FERC Program Director, noting that every member of the FERC staff have the lived experience of supporting a loved one with mental illness.

As one in four Americans either suffer with a mental illness themselves or has a family member so dealing, the services provided by FERC are crucial. Plus, in challenging economic times, the strain on individuals and families is even greater. To help meet that need — and meet the need in ways that are most comfortable to their clients — FERC provides both in person and telephone support. All services are free. 

“We call it our ‘warm line’ telephone service,” says Foote. “There is still so much misunderstanding, fear and therefore much stigma around issues of mental health and illness; it is sometimes easier for our clients to discuss their needs over the phone.” Also, cultural competency is a vital part of our mission. “We meet our clients where they are in terms of their ability to cope with their own and the struggles of their loved ones,” says Annie Kim, Lead Family Advocate.

Staff at FERC help individuals navigate the often complex web of behavioral health services. When needed, FERC staff will even make the initial contact or appointment with an agency on behalf of an individual. In addition, FERC staff assist with locating resources such as mental health care, housing, day programs, and recreation, and offer guidance about managing family relationships and developing coping strategies. “We direct people to available and appropriate services,” says Kim. People who contact FERC in the midst of a crisis may be directed to the appropriate crisis management services.

As a new program of the Mental Health Association of Alameda County (contracted for service with ACBHCS), FERC has been reaching out to clients and organizations to offer their services. Staff members are available not only on site, but also to facilitate or take part in support groups for other organizations. As FERC continues to grow, staff also plans to develop support groups for transition age youth (15-27) who have a family member with a mental illness and to provide education about mental illness for classroom teachers.

FERC’s main office is in Oakland’s Eastmont Town Center (7200 Bancroft Avenue, Suite 269), with additional offices in Fremont and Hayward. A site in Livermore will open later this fall. Office hours are Monday through Friday, 9am-5pm and people from anywhere in Alameda County are welcome to drop in with questions or to conduct research in the library or on the Internet.

“For many years, we envisioned a safe harbor for people in Alameda seeking mental health services,” said Margot Dashiell, Chairperson of the Alameda County Family Coalition, speaking at the October 7^th event. “FERC has become that safe harbor.”

The Family Education and Resource Center (FERC) is a new and innovative family/caregiver-centered program that will provide information, education and support services to family/caregivers of children, adolescents, transitional age youth, adults or older adults with serious emotional disturbance or mental illness living in all regions of Alameda County. These services will be provided in a culturally competent manner, reaching out to people of all ethnicities. For more information about FERC, call 510-746-1700. To access services, families can call 1-888-896-FERC (3372).

Click here to see all recent news from this company

NEW ROCHELLE, NY–(Marketwire – October 12, 2010) –  Somnia Anesthesia, the premier anesthesiology practice management company, today announced the appointment of John Ansorge to the position of chief financial officer. In this newly created role, Ansorge will assume oversight of the company’s financial operations, with responsibility for accounting, financial planning and reporting, budgets and forecasting. He will report to Somnia President and CEO, Marc E. Koch, MD, MBA.

Mr. Ansorge joins Somnia with more than 20 years’ experience in hospital finance. Most recently, he held the position of interim CFO for Stamford Health System in Stamford, Connecticut, a 305-bed teaching hospital affiliated with the Columbia University Medical School and posting net revenues of $450M. While there, he reorganized the Patient Access Department, initiated and controlled a cost savings plan aimed at reducing expenses, reduced supply costs, and successfully reorganized the hospital’s debt during unfavorable market conditions.

“John is a highly talented healthcare finance professional who rounds out our world-class executive team,” said Dr. Koch. “He brings tremendous business acumen to the organization and we’re confident he will put in place the financial structure needed to support our continued growth in the hospital market.”

Prior to joining Stamford Health System, Mr. Ansorge held the post of chief financial officer at a variety of hospitals including Lincoln Park Hospital and Ephraim McDowell Regional Medical Center, located in Chicago and Kentucky, respectively. While at Lincoln, he reduced cash flow losses and increased collections. He also moved the hospital’s EBITA results into positive territory for the first time in five years.

Earlier in his career, Mr. Ansorge honed his healthcare accounting and finance skills in a series of roles requiring increasing levels of responsibilities at Humana, Inc. and Columbia/HCA Healthcare Corporation.

Mr. Ansorge holds a BS, Healthcare Management, from the University of Alabama.

About Somnia
Somnia Inc., founded in 1996, is the most experienced physician-owned and operated clinical anesthesia management company servicing healthcare facilities nationwide. Somnia specializes exclusively in building and comprehensively managing world-class anesthesia teams that consistently deliver the highest quality of patient care. The company expertly manages all areas of anesthesia including leadership, recruiting, revenue cycle management, payor contracting and quality assurance with the largest in-house management infrastructure in the United States.

For more information visit: www.somniainc.com. Follow us on Twitter: http://www.twitter.com/somniainc.
Add us on LinkedIn: http://www.linkedin.com/in/somniaanesthesia.

Click here to see all recent news from this company

DALLAS, TX–(Marketwire – October 12, 2010) –  For the entire month of October, Pizza Patron will be raising funds in all its stores for the St. Jude Children’s Research Hospital.

Pizza Patron stores have St. Jude posters and counter top displays up that explain why and how to donate. St. Jude is a pediatric treatment and research facility in Memphis, Tennessee which treats children with cancer and other catastrophic diseases. Founded by entertainer Danny Thomas on the premise that “no child should die in the dawn of life,” the hospital is well-known for being the only pediatric cancer center in the country that won’t charge parents for any treatment not covered by their insurance plan. No child is ever turned away from St. Jude’s because of his or her family’s inability to pay.

“We were really amazed by the professionalism and support shown by St. Jude’s team. They visited every Pizza Patrón across the country personally, and provided training to our team members,” said Andrew Gamm, brand director for Pizza Patrón. “The response from our employees has been overwhelmingly positive; everyone is very excited to play a part in helping this amazing charity.”

Gamm explained that donations of any size can be given and the donation will be indicated on the receipt in a separate line item. One-hundred percent of the money raised will go to St. Jude’s. 

In 2010, St. Jude Children’s Research Hospital was named the number one children’s cancer hospital in the United States by U.S. News & World Report. Discoveries at St. Jude have changed how doctors treat children with cancer and other catastrophic illnesses. Since St. Jude was established, the survival rate for acute lymphoblastic leukemia, the most common type of childhood cancer, has increased from 4 percent in 1962 to 94 percent today. St. Jude has treated children from across the U.S. and from more than 70 countries. Doctors around the globe consult with St. Jude on their toughest cases. Additionally, St. Jude has an International Outreach Program to improve the survival rates of children with catastrophic illnesses worldwide through the transfer of knowledge, technology and organizational skills.

About Pizza Patrón
Pizza Patrón, America’s #1 Latin pizza brand, offers traditional pizza, wings and sides in its community based, Latin-influenced stores. Pizza Patrón was founded by restaurateur Antonio Swad in 1986, in Dallas, Texas, and today operates 100 dine-in and carry-out restaurants in seven states with 40 more under development. Pizza Patrón has franchise opportunities available in prime markets throughout the country offering a proven system for hard-working franchisee candidates. In 2007, the brand received international news coverage when it decided to accept Mexican Pesos at all of its locations, gaining over 500,000,000 media impressions worth over $30 million in the U.S. alone. The company’s medium AMIGO PIZZAS® start as low as $4 and X-Large LISTA-NOW READY™ pepperoni pizzas start as low as $6 all day, every day.

Website – www.pizzapatron.com
Facebook – http://www.facebook.com/pizzapatron
Twitter – http://www.twitter.com/pizzapatron
MySpace – http://www.myspace.com/mypizzapatron
YouTube – http://www.youtube.com/user/pizzapatroncorp

Click here to see all recent news from this company

IRVINE, CA–(Marketwire – October 12, 2010) –  SK&A, A Cegedim Company, today announced results of its ongoing survey of U.S. medical offices to determine the policies for allowing pharmaceutical and other medical industry sales-rep access to physicians and other prescribers. The Physician Access survey is based on completed telephone interviews with more than 237,000 medical sites representing 680,000 physicians.

While other similar studies and services are based on sample surveys, projections and manufacturer-based data, SK&A has invested in a comprehensive, ongoing survey to directly profile every U.S. medical office and record their exact policies for contact with sales reps. SK&A surveys its Office-Based Physician database every six months from its Research Center in Irvine, California.

After three years of measuring access to physicians, what has emerged is a portrait of doctors and their willingness to interact with sales representatives. Nearly half of the physicians surveyed say they require or prefer appointments to be made by reps prior to one-on-one meetings, while about 23 percent of doctors refuse to see sales reps at any time at any of their practice locations.

According to the survey, the percentage of doctors who will not allow access unless an appointment is scheduled increases measurably when their practices are owned by hospitals or health systems. In many cases, the appointment must be made through a headquarters location rather than the practice site itself.

“As prescribers become busier and less accessible, understanding physician access preferences is critical to successful sales and marketing resource planning, and execution,” said SK&A’s Dave Escalante, Vice President of Data and Information Solutions. “The information available from SK&A’s up-to-date profiling of physician access gives sales and marketing organizations deeper insight, enabling them to target more efficiently while not jeopardizing important relationships.”

Managing sales-rep calls is a significant part of the physician work week. According to the latest findings of the Physician Access study, most doctors (98 percent) report their offices are visited by up to 20 industry reps per week or one rep an average of every two hours.

Other significant trends found within the survey include:

• Specialty physicians are less likely to grant sales reps access than general practitioners. The top-three most accessible physician areas are allergists/immunologists (4.2% no-see rate), orthopedic specialists (5.1%) and diabetes specialists (7.6%). The least accessible physicians are diagnostic radiologists (92.1% no-see rate), pathologists (91.8%) and neuroradiologists (90.6%).The access rates for these specialists have remained constant for the last two bi-yearly reporting periods.

• Offices with fewer patients seen daily are less likely to see sales reps. Sites with a daily patient volume of one to 10 have a no-access rate of 28.9 percent, while those with a daily patient volume of 31 to 40 have a 13.4 percent no-access rate. Sites that are less busy are often staffed by one physician who is not able to take a break from patient appointments to visit with industry sales reps.

• Health system- and hospital-owned offices are less likely to grant sales reps access. Health system- and hospital-owned offices have no-access rates of 30.8 percent and 29.6 percent, respectively. Non-health system and hospital-owned offices have no-access rates of 21.4 percent and 21.7 percent, respectively.

• Larger practices are less likely to grant sales reps access. Offices with one to two physicians have a no-access rate of 13.3 percent while offices with 10 or more physicians have a no-access rate of 42.2 percent.

• Physician offices in the Western U.S. are least likely to allow sales reps access. The South had the lowest no-access rate of 19.4 percent, and the West had a 28.4 percent no-access rate.

The Physician Access report is available to help healthcare marketers and sales executives in appointment-setting and connecting personally with physicians. SK&A has compiled access data at the physician level and offers custom databases selectable by geography, specialty, office size, patient volume, practice ownership and other variables upon request. 

Editor’s Note: For a copy of the summary findings for publication, please contact Jack Schember, SK&A Director of Marketing, at 800-752-5478, ext. 1259. 
 
About SK&A, A Cegedim Company:
SK&A is a leading provider of healthcare information solutions and research. SK&A, as part of Cegedim’s global OneKey® offering, researches and maintains contact and profiling information for over two million healthcare practitioners, including 800,000-plus prescribers. SK&A also offers the only 100-percent telephone-verified database of email addresses of U.S. prescribers and professionals working at active healthcare sites. SK&A’s customers include many of America’s most recognized healthcare, life sciences and pharmaceutical companies. Please visit www.skainfo.com for more information or www.skalivecounts.com for counts and ordering. 

About Cegedim:
Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, life sciences companies, healthcare professionals and insurance companies. The world leader in life sciences CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs 8,600 people in more than 80 countries and generated revenue of EUR 874 million in 2009. Cegedim SA is listed in Paris (EURONEXT: CGM).
To learn more, please visit: www.cegedim.com

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – October 12, 2010) –  Healthnostics, Inc., (PINKSHEETS: HNSS), a medical manufacturing and biotechnology analytics company, has purchased a major manufacturer of specialty medical products. There will be an immediate positive impact on revenue and earnings commencing in the 1^st Quarter of 2011. Details will be forthcoming in subsequent press releases.

“This accretive purchase directly ties into the Company’s recent acquisition of World Wide Wipes Co., and it will result in even more substantial impact on our profitability and earnings per share,” said Alan Grofe, president.

About Healthnostics

Healthnostics, Inc. is a medical and biotechnology analytics company that provides comprehensive patient clinical monitoring and risk management systems to acute care hospitals and utilizes its Internet portals to deliver medical and biotechnology resource information to industry professionals as well as to the general public. Healthnostics’ major products include: Worldwide Wipes Co., a manufacturer and distributor of medical and other wipes, MedGuardian, a patient care monitoring and risk management system for hospitals that is fully Web-based; and through the MedBioWeb subsidiary, MedBioWorld™, one of the largest professional medical and biotechnology directory resource and reference portal sites on the Internet, and FamilyMedicalNet, a companion consumer healthcare information portal.

For further information please visit Healthnostics www.healthnostics.com, and Worldwide Wipes Co. www.wipesco.com, MedBioWorld www.medbioworld.com, and FamilyMedicalNet www.familymedicalnet.com. And visit us on Facebook at www.facebook.com/Healthnostics.

This press release may contain certain statements that are not descriptions of historical information, but are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934. These forward-looking statements refer to matters that involve risks and uncertainties. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated.

SAN DIEGO, CA–(Marketwire – October 12, 2010) –  MIR3, the innovator of real-time Intelligent Notification™ and response technology, today announced that Concerro, provider of SaaS-based workforce management and emergency response systems that facilitate real-time information access, has chosen inEnterprise™ software to integrate with their software offerings and to resell as a stand-alone product.

Concerro has been using inEnterprise to add Intelligent Notification to their flexible workforce management system, ShiftSelect™, for more than two years. They have not only renewed their contract, but extended it to include development within their CommandAware™ emergency response and incident management system and have also agreed to act as resellers of the stand-alone inEnterprise platform. Now Concerro is able to offer their customers both a command console with integrated notification and a separate platform that can be used for important message delivery and mass notification.

“With MIR3, we can offer our customers real-time notification that helps communicate important messages among hospital staff wherever they are, no matter what communication device they use,” said Michael Meisel, VP of product management and marketing for Concerro. “Any number of users can be alerted of an urgent staffing need or emergency situation quickly and simultaneously, which saves time and improves communication when it’s needed the most.”

“The partnership between MIR3 and Concerro supports our strategy of penetrating the healthcare and hospital industries and provides solid benefits to both partners,” said Rene Grossrieder, VP, worldwide channels and alliances for MIR3. “Expanding on our partnership, both from a development and reseller standpoint, provides hospitals with the most comprehensive solution on the market. These new solutions will help them to take action more quickly, streamline costs and enhance compliance.”

ShiftSelect is a workforce management system used to improve shift visibility and align organization and workforce needs in a hospital setting. CommandAware is an emergency response and incident management system for hospitals that helps these institutions become HICS IB and NIMS compliant as well as meet Joint Commission preparedness standards.

inEnterprise uses Intelligent Notification technology to decrease time spent on manual and often unreliable means of contacting staff, vendors and partners, allowing users to deliver important messages to hundreds or thousands of people at once, no matter where they are and by a wide variety of communication means. Intelligent Notification technology will provide Concerro customers with an automated way to increase and improve communications, augmenting their workforce management and disaster response systems. 

ABOUT MIR3

MIR3, Inc. is the leading developer of Intelligent Notification and response software, which helps organizations enhance communication abilities, protect assets, and increase operational efficiency. MIR3 technology enables advanced rapid, two-way mass communication for IT, business continuity, and enterprise operations for more than 85 of the FORTUNE 100 companies, as well as government entities, universities, and companies of all sizes in more than 130 countries. For more information, visit www.mir3.com.

ABOUT CONCERRO

Concerro is a healthcare Software-as-a-Service (SaaS) company that provides healthcare workforce and emergency response and incident management systems that improve both quality of life and your bottom line by reducing costs through optimization rather than reduction. The company has won numerous awards and recognition, including being named to the prestigious Inc. 5000 for three consecutive years, and receiving Red Herring’s 100 most promising private technology ventures in North America and Best of SaaS Showplace (BoSS) awards. To learn more, visit www.concerro.com, or follow Concerro on Twitter.

BOCA RATON, FL–(Marketwire – October 12, 2010) –  David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that the Company completed the sale of $2.75 million principal amount, 10% convertible notes due in 2012 and warrants to purchase an aggregate of 6,111,000 shares of Vicor’s common stock on October 8, 2010. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i^® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that accurately risk stratify specific target populations for future pathological events, including congestive heart failure patients for cardiac death resulting from arrhythmia or pump failure, diabetics for diabetic autonomic neuropathy (DAN), and trauma victims for imminent death absent immediate lifesaving intervention.

“We’re extremely pleased to have secured this financing, especially given the current state of the economy. We are gratified by our investors’ confidence in the market potential of our non-invasive risk stratification products, which we are beginning to realize. This financing will provide us with the working capital needed to continue to execute our business plan,” stated Mr. Fater.

About Vicor Technologies, Inc.
Vicor Technologies is a biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i^®). The PD2i^® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

Vicor currently has three products employing the PD2i^® nonlinear algorithm. The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability; physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in multiple clinical trials, identifies patients at risk of sudden cardiac death.

Vicor anticipates additional applications employing the PD2i^® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

Disclaimer
The appearance in this release of name-brand institutions, such as the U.S. Army Institute for Surgical Research, does not constitute endorsement by these institutions of the information, products, or services contained therein.

Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to successfully complete the normal range study for PD2i^®values; our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain FDA approval of our 510(k) submission to secure a claim for the PD2i CA™(Cardiac Analyzer) for risk stratifying congestive heart failure patients at elevated risk of cardiac mortality and our ability to obtain marketing clearance from the FDA for the PD2i VS™ (Vital Sign) for military and civilian applications; our ability to develop additional applications for the PD2i^®algorithm; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 10-19

Click here to see all recent news from this company

MADISON, WI–(Marketwire – October 12, 2010) – TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for cancer care, saw attendance double over 2009 levels for its annual Asia Pacific User Education Symposium, held October 2-3, 2010, in Incheon, South Korea. More than 190 TomoTherapy^® treatment system users from across the Asia Pacific region convened to share insights on a growing body of clinical evidence of the efficacy of TomoTherapy radiation treatments. The increased attendance underscores the rapid adoption of the solution in the region, where the installed base of TomoTherapy systems has increased by 27 percent in just the last year.

“The Asia Pacific User Education Symposium was extremely valuable for all TomoTherapy users in the region,” said Dr. Yong Chan Ahn, associate professor and chairman of Radiation Oncology at Samsung Medical Center in South Korea, who also served as chairman of the event. “We had the opportunity to see a great deal of excellent clinical research, with many presentations focused on those diseases, such as liver cancer, that are difficult to treat and commonly seen in Asia. I look forward to the maturing of the results we are seeing, further showing the benefits of TomoTherapy in these areas.”

The Asia Pacific region is one of the fastest growing markets for TomoTherapy, with its installed base experiencing consistent growth of about 30 percent annually for the last few years. The key growth drivers for the region have been Korea, Japan and, more recently, China. Also, in the past year, expansion into Malaysia and Australia have added to the growth. Japan remains the largest market in the Asia Pacific region with 19 TomoTherapy systems installed, second overall only to the United States. South Korea is the second largest market in the region, with 14 systems currently installed.

“We were extremely pleased to see the representation of our customers at this meeting. Their presence overwhelmingly confirms that TomoTherapy offers very high quality treatment and is considered the gold standard in radiation therapy,” said H.W. Jang, CEO of Oncology Total Solutions, a distributor of TomoTherapy technology in South Korea and host of the symposium. “We are proud to have a very strong relationship with TomoTherapy to provide the best quality service, which strengthens our bond with our customers and helps them in the delivery of treatment to their patients.”

The User Education Symposium featured a strong scientific program covering topics from treatment of liver and nasopharynx cancers, to sparing of the hippocampus during treatment for brain cancer. Of particular note were two presentations:

• Dr. Chul Seung Kay of Incheon St. Mary Hospital of Korea presented on five years of clinical experience with TomoTherapy technology at his institution, citing multiple areas of investigation. In the treatment of advanced hepatocellular cancer with TomoTherapy, results showed a median survival rate double that of similar patients treated by other means. Other disease studies showed positive response to TomoTherapy treatments, particularly patients with pulmonary metastases who did not respond to multiple cycles of systemic chemotherapy. Researchers also reported on the feasibility of TomoTherapy to treat inoperable, advanced pancreatic cancers, and discussed ongoing studies on extracranial metastases, re-irradiation of recurrent rectal, head and neck cancers and oligometastases from breast cancer.

• Dr. Chikao Sugie of Nagoya City University, Japan detailed his center’s experience with craniospinal treatments on a group of 12 patients, median 14 years of age. For treatment of various brain tumors, TomoTherapy plans were superior to conventional linear accelerator-based plans with regard to the homogeneity and conformality in planning target volume.

“We have treated more than 1,300 patients with a broad spectrum of disease with TomoTherapy since September 2006,” said Dr. Pei-Wei Shueng, chief of Radiation Oncology at Far Eastern Hospital in Taiwan. “We have found that helical TomoTherapy provides us with a flexible treatment fractionation scheme that offers better dose coverage and highly conformal dose distributions, combined with an impressive ability to simultaneously spare multiple critical structures.”

“The degree of clinical interest in TomoTherapy in the Asia Pacific region is very impressive, as evidenced in the participation in our symposium. In just its third year, the Asia Pacific User Education Symposium has grown to be the largest one TomoTherapy hosted this year,” said Fred Robertson, M.D., TomoTherapy’s CEO. “Based on the response to our symposium and the clinical evidence coming out of the region, we believe that the stage is set for continued significant adoption of the TomoTherapy platform throughout the Asia Pacific region.”

The Asia Pacific event is the final in a series of three User Education Symposia held in 2010. The first, for the Americas region, took place in April in San Diego, Calif., and the second, for Europe and the Middle East, was held in May in Marbella, Spain. 

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy^® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art^® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD^™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

Forward-Looking Statements
Statements in this release regarding future products or product capabilities, events, expectations and other similar matters, including but not limited to statements using the terms “may,” “should,” “suggests” or “indicates” constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to factors such as our ability to integrate acquired assets, ability to protect intellectual property, risks of interruption due to events beyond the company’s control, and the other risks listed from time to time in TomoTherapy’s filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. These forward-looking statements represent TomoTherapy’s judgments as of the date of this press release. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries

TARPON SPRINGS, FL–(Marketwire – October 11, 2010) – Pinnacle Home Care of Pinellas today announced that it has been named one of the top 500 home health agencies in the country, according to the 2010 HomeCare Elite™. Now in its fifth year, the HomeCare Elite identifies the top 25 percent of home health agencies in the United States and further highlights the top 100 and top 500 agencies overall. Winners are ranked by an analysis of performance measures in quality outcomes, quality improvement, and financial performance.

“The 2010 HomeCare Elite winners continue to demonstrate a commitment to providing their patients with the best possible care while performing at the highest level,” said Amanda Twiss, CEO of OCS HomeCare. “We congratulate Pinnacle Home Care of Pinellas on being one of the top home care agencies in the country. In addition, we salute all forward-thinking providers who are already working on measuring and improving their performance using OASIS-C outcomes and process measures and HH-CAHPS results. This important data will also be used in identifying the HomeCare Elite in the future.”

Pinnacle Home Care’s co-owner, Margo McElveen, RN, credits “staff commitment to exceeding both patient and physician expectations as well as the staff’s compassion when delivering quality of care” with the company’s ability to rank as one of the HomeCare Elite. “Our staff’s dedication to individualized patient care and their successful outcome is what sets us apart,” she said.

 “On the fifth anniversary of HomeCare Elite, DecisionHealth would like to congratulate all of the winners who have achieved excellent clinical and financial outcomes, especially during times of such drastic regulatory changes,” added Marci Heydt, executive editor of DecisionHealth’s Home Health Line.

The 2010 HomeCare Elite is the only performance recognition of its kind in the home health industry. The 2010 HomeCare Elite is brought to the industry by OCS HomeCare, the leading provider of homecare information, and DecisionHealth, publisher of home care’s most respected independent newsletter Home Health Line. The data used for this analysis were compiled from publicly available information. The entire list of the 2010 HomeCare Elite agencies can be viewed by visiting the OCS HomeCare website at www.ocshomecare.com.

MUNDELEIN, IL–(Marketwire – October 11, 2010) –  The more than 4,000 healthcare workers and breast cancer survivors who danced in the Pink Glove Dance: The Sequel video are still working to raise awareness for breast cancer prevention — and maybe inspire more people to dance and support the cause. Medline Industries, Inc. — the makers of the pink gloves and creator of the dance videos — has just posted videos from each of the 12 healthcare facilities and breast cancer survivor groups that participated in the Pink Glove Dance sequel. The videos can be viewed at www.pinkglovedance.com.

“Our video involved doctors and nurses, employees, students, survivors and others from the IU Simon Cancer Center, the IU school of nursing and medicine, and Clarian Health,” said Michael Schug, communications specialist at the Indiana University Melvin and Bren Simon Cancer Center. “So, a lot of our people danced to help spread the word about breast cancer awareness. To let our dancers and community know about our custom video, we have done mass e-mailings, posted it on our Facebook pages, YouTube channels, and Flickr accounts. It’s definitely gone viral around here.” 

Linda Rumore, purchasing agent for Thibodaux Regional Medical Center in Thibodaux, Louisiana, and the coordinator of the shoot at the hospital said: “The video is such a morale booster for all of us throughout the hospital because it’s such a great cause. It’s like Christmas Eve here because everyone is so excited and honored to be involved in the video.”

The original Pink Glove Dance video was launched about a year ago with healthcare workers at Providence St. Vincent Medical Center in Portland, Oregon. Because of the overwhelming response from the video (now with more than 11.8 million views on YouTube), Medline went across the country and into Canada to film healthcare workers and breast cancer survivors dancing in pink gloves to raise awareness for breast cancer prevention. The result was The Pink Glove Dance: The Sequel, which was launched September 17, featuring workers from 11 hospitals, three nursing homes and breast cancer survivors in five different locations from the Golden Gate Bridge to New York’s Times Square and several points in between. (See list of participating facilities and locations at the end of this release.)

“I cannot begin to tell you what participating in the video does for someone like me — a survivor. After going through hell and back and being able to have fun, dance and share these moments, it’s amazing and it shows how Medline really cares and thinks about the people they are serving,” said Annette Rodriguez, a New York City resident and participant in the survivor shoot in Times Square. “Being in the video shows that we aren’t just pieces of meat being dealt with, we are people too. People aren’t noticing the lack of hair or how skinny or fat someone is getting from treatments. It made all of us feel beautiful and allowed us to just have fun, let loose.” 

Since the original video was released last November, the Pink Glove Dance has grown way beyond Medline’s efforts. In the past year, more than 80 pink glove videos have been posted on YouTube from around the world (including Germany, The Netherlands and Canada) featuring people dancing in pink gloves to support breast cancer awareness. Some of the more interesting videos feature the Penn State women’s basketball team, students in elementary schools, high school cheerleaders, grandmothers, and even cats and babies wearing pink gloves.

Medline originally developed the pink exam gloves and the Pink Glove Dance video as a way to spread awareness for breast cancer prevention.

“Breast cancer awareness and prevention is now the largest philanthropic cause in our company,” said Andy Mills, president of Medline. “The pink gloves are symbolic of healthcare workers’ connection with breast cancer patients. Prevention and early detection are among the most important ways you can fight breast cancer and that is why our campaign focuses on helping fund mammograms for women who cannot afford them.”

Medline donates $1 to the National Breast Cancer Foundation for every case sold of its pink gloves to help fund mammograms for underserved women. Medline has donated more than a half million dollars to provide education and free mammograms to those in need and continues to make contributions every year.

About Medline
As the nation’s largest privately held manufacturer and distributor of medical supplies, Medline is focused on helping to improve the quality of care for patients and residents. Breast cancer awareness is a natural extension of Medline’s corporate mission to help save lives through the early detection of breast cancer. (Visit www.medline.com/breast-cancer-awareness for details). Based in Mundelein, Ill., Medline manufactures and distributes more than 100,000 products to hospitals, extended care facilities, surgery centers, home care dealers and agencies, and other markets.

Who is in the sequel?
The sequel features more than 4000 healthcare workers and breast cancer survivors from 14 separate facilities in the U.S. and Canada (11 hospitals, 3 nursing homes and 5 separate breast cancer survivor shoots). Here is a list of participating locations:

Providence St. Vincent Medical Center
Portland, Oregon

University of Minnesota Medical Center, Fairview
Minneapolis, Minnesota

Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana

Tallahassee Memorial Healthcare, Inc.
Tallahassee, Florida

Saint Michael’s Medical Center
Newark, New Jersey

The Medical Center of Plano
Plano, Texas

HCA Johnston?Willis Hospital
Richmond, Virginia

Scripps Memorial Hospital La Jolla
La Jolla, California

Sky Ridge Medical Center
Lone Tree, Colorado

Thibodaux Regional Medical Center
Thibodaux, Louisiana

Capital Health
Halifax, Nova Scotia

Burgess Square Healthcare and Rehab Centre
Westmont, Illinois

Isabella Geriatric Center
New York, New York

Lorien Health Systems
Maryland

Breast Cancer Survivor Sites
New York City
Chicago
San Francisco
Minneapolis
Portland

ALEXANDRIA, VA–(Marketwire – October 11, 2010) – The American Diabetes Association launched its first official blog today to help put a face on a disease that kills more people each year than breast cancer and AIDS combined. The blog, called Diabetes Stops Here: Living with Diabetes; Inspired to Stop It, aims to document the Stop Diabetes® movement by reaching and engaging the 23.6 million Americans living with diabetes as well as the 57 million who are at risk for developing type 2 diabetes. 

Diabetes Stops Here will provide snap shots of the people who are committed to putting an end to this disease, from inspiring volunteer stories to moving staff experiences to celebrity stories about how to be successful while living with diabetes. The stories, interviews and news will be shared by the blog’s author, a staff member at the American Diabetes Association, who has lived with type 1 diabetes for nearly ten years. 

The Stop Diabetes movement was launched during American Diabetes Month® in November 2009 as a call to action for people to stand up against this disease and its devastating complications. The Association hopes to have one million people join the movement by the end of 2010.

“There have been so many touching moments in the movement to Stop Diabetes since we launched last year,” commented Larry Hausner, CEO, American Diabetes Association. “People have shared courageous stories of facing their diabetes head on, while others have shared their heart-breaking experiences of losing a loved one because of diabetes. The blog is a new way to raise our collective voices and tell people why we need to Stop Diabetes once and for all.” 

Some of the most vocal diabetes stories come from blogs and other social media platforms which create a broad online community of people who have diabetes or whose loved ones are living with the disease. “By means of this blog,” noted Hausner, “we hope to add our voice to this dialogue and further engage with those who may be well aware of the effects diabetes can have on their lives.”

Today’s first post is titled “Why ‘Stop Diabetes’?” can be found at www.diabetesstopshere.org. This initial post seeks to explain why the Stop Diabetes movement was created and its goal for engaging the public. “The goal of the Stop Diabetes movement is to grow to epic proportions, to be bigger than the disease itself,” the blog explains. “In short, it’s the answer to why the Association does the work that it does.”

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

COLUMBIA, SC–(Marketwire – October 11, 2010) – BDI Pharma, Inc. (BDI), the nation’s fastest growing national distributor of biotech therapies, announced the continuing expansion of the company’s specialty pharmaceutical portfolio with the launch of a new Animal Health Division, 4legPharma. This latest BDI Pharma expansion, focused on the biopharmaceutical needs of the veterinary specialist, is supported by the launch of its own website, www.4legpharma.com, as well as a staff of highly trained representatives dedicated to service this unique marketplace.

“As the Animal Health Division of BDI Pharma, 4legPharma is backed by over 15 years of experience in handling urgent need, critical care pharmaceutical products. We are uniquely positioned to offer veterinary specialists the best of both animal drugs as well as human therapies for extralabel use to treat pets suffering from the same chronic, life-threatening conditions that affect humans. Our customers appreciate that we deliver the safety of a secure product distribution channel and a level of personal service that is unrivaled in the veterinary medical community,” said Angela Phillips, Director of Animal Health.

The US Bureau of Labor Statistics states that the number of veterinary jobs is expected to increase thirty-three percent (33%) by 2018 as a whole, and reports published by the AVMA indicate an average annual increase of eleven percent (11%) in the number of veterinarians seeking board-certification to specialize in the areas of internal medicine, anesthesiology, dermatology, and seventeen other recognized specialties.

“At BDI Pharma, it is our commitment to bring definable value and uncompromising service to our customers and trade partners that sets us apart from others,” stated Edward Stiefel, Jr., Co-President of BDI Pharma. “Our Animal Health Division is a testament to the capabilities and resources we are willing to dedicate to service the specific nature of a growing marketplace.”

About BDI Pharma, Inc.

Since 1995, BDI Pharma has defined its customer-centric approach to serving the nation’s healthcare community through innovative inventory supply solutions, unparalleled customer service, extensive product knowledge, 24/7 emergency availability and urgent need delivery. An open-access resource for reference material, educational literature, market data and online ordering, www.bdipharma.com has become an industry renowned point of reference. Proprietary programs for product consignment (www.consignadvantage.com), flu vaccine pre-booking (www.securiflu.com), vaccine ordering (www.securivax.com) and purchasing/reward programs (www.qoreprogram.com and www.securigam.com) round out a family of solutions tailored to the needs of the healthcare community at large.

BDI Pharma’s portfolio includes branded and generic specialty pharmaceuticals, chemotherapy products, vaccines, albumin, IVIG, coagulation factors, high-titer or “hyper” immune globulins, and other specialty injectables. BDI Pharma is recognized as an “ADR,” or Authorized Distributor of Record, for all of the manufacturers it represents.

DALLAS, TX–(Marketwire – October 11, 2010) –  JC Data Solutions (PINKSHEETS: JCDS), a provider of innovative and cost-effective solutions for digital office workflow and data management focusing on the Oil & Gas, Legal and Healthcare industries, has entered into an agreement to provide their Payment Manager™ services to Legacy Reserves, LP of Midland, TX.

The Payment Manager™ software, designed by JCDS especially for the Oil & Gas Industry, is part of a turnkey service that automates the distribution, delivery and archival of payments and documents to payees through ACH/EFT and posts documents to the web. The service also offers printing checks and/or statements, joint interest billing and other cost-effective data management functions.

Legacy, a public company traded on the NASDAQ under symbol LGCY, is an independent oil and natural gas limited partnership headquartered in Midland, Texas, specializes in Oil & Natural Gas Operations in the Permian Basin and Mid-Continent Regions focusing on the acquisition and development of oil and natural gas properties.

Cary Allen, CEO of JCDS, said, “Legacy Reserves is growing and recognized the need to streamline some of their processes. Payment Manger™ provides several key operational advantages as well as significant reduction of paper and manpower associated with their distribution process.”

Forward-Looking Statements

This press release contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are “forward-looking statements” are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties or other factors which may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as: the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels.

All information in this release is as of the date of this release.

MONMOUTH JUNCTION, NJ–(Marketwire – October 11, 2010) –  CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, was chosen to present at the AdvaMed 2010 MedTech Conference at the Walter E. Washington Convention Center in Washington, D.C. next week. Dr. Phillip Chan, Chief Executive Officer, will speak Wednesday, October 20, 2010 at 10:10AM EDT in Room 204a.

http://www.advamed2010.com/go.cfm?do=Page.View&pid=80

Following the meeting, the presentation will be made available on the company’s investor relations website: http://www.cytosorbents.com/invest.htm

About AdvaMed 2010

AdvaMed 2010 is the premier MedTech conference for business leaders, entrepreneurs, policy-makers, media, financiers, and other industry stakeholders from around the world. In only its third year, AdvaMed 2009 attracted 1,400 industry leaders — including 500+ CEOs, Presidents and C-level executives. For more information, visit www.AdvaMed2010.com.

About CytoSorbents and CytoSorb™

CytoSorbents Corporation, and its operating subsidiary CytoSorbents, Inc., is a critical care focused therapeutic device company in clinical trials to treat severe sepsis, often called “overwhelming infection,” with a novel blood purification device called CytoSorb™. Severe sepsis afflicts more than 1 million people in the United States and an estimated 18 million people worldwide each year, killing one in every three patients despite the best treatment. In the United States, more die from severe sepsis than from either heart attacks, strokes or any single form of cancer. Severe sepsis is typically triggered by bacterial infections like pneumonia, or viral infections like influenza. However, it is the body’s abnormal immune response to the trigger that leads to severe inflammation and the unregulated, massive production of cytokines, often called “cytokine storm,” that then causes multi-organ failure and often death. CytoSorb™ is a cartridge containing highly porous polymer beads that are designed to filter cytokines and treat potentially fatal cytokine storm. As blood is pumped repeatedly through the CytoSorb™ cartridge using standard dialysis equipment, the beads bind and remove cytokines and other toxins from blood. The treated blood is then returned to the patient. The Company is currently conducting its European Sepsis Trial — a multi-center, randomized, controlled clinical trial using CytoSorb™ to treat up to 100 patients with severe sepsis in the setting of respiratory failure. Pending a successful trial, the Company will seek CE Mark approval and commercialization of CytoSorb™ in the European Union. Importantly, cytokine reduction via CytoSorb™ has broad applicability to a number of other critical care diseases where cytokine storm plays a detrimental role, including burn and smoke inhalation injury, trauma, acute respiratory distress syndrome, advanced influenza, acute pancreatitis and other. CytoSorb™ is one of a number of different resins designed for various medical applications, including improved dialysis, the potential treatment of inflammatory and autoimmune disorders, rhabdomyolysis in trauma, removal of chemotherapy during treatment of cancer with high dose regional chemotherapy, drug detoxification and others. Additional information is available for download on the Company’s website: www.cytosorbents.com

Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management’s current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. CytoSorbents Corporation and CytoSorbents, Inc believe that its primary risk factors include, but are not limited to: obtaining government approvals including required FDA and CE Mark approvals; ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company’s medical devices in the marketplace; the outcome of pending and potential litigation; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company’s products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company’s Form 10-K filed with the SEC on April 9, 2010, which is available at http://www.sec.gov.

LOS ANGELES, CA–(Marketwire – October 8, 2010) –  MMRGlobal, Inc. (OTCBB: MMRF) (the “Company”) today announced that David A. Boyden, a member of MMRGlobal’s Board of Directors (the “Board”) since January 2009, has notified the Company of his intent to resign from the Board, effective today. There were no disagreements between the Company and Mr. Boyden which led to his decision to resign.

“Dave joined the Board at the request of the pre-merger Faville, Inc. Board of Directors and has contributed to the Company’s efforts in the exploitation of its biotech assets. He is not resigning due to disagreements with the Company or its officers over operations, policies or practices,” said Robert H. Lorsch, MMRGlobal Chairman and CEO. “We appreciate Dave’s many contributions to the Company since the merger and I will miss his involvement. The Company plans on a search for a replacement director with expertise in biotech, insurance or banking.”

About MMRGlobal, Inc.

MMR Global, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMR Global, Inc. and its products, visit www.mmrglobal.com.

Forward-Looking Statements

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements, and some can be identified by the use of words (and their derivations) such as “need,” “possibility,” “offer,” “development,” “if,” “negotiate,” “when,” “begun,” “believe,” “achieve,” “will,” “estimate,” “expect,” “maintain,” “plan,” and “continue.” MMRGlobal, Inc. disclaims any intent or obligation to revise or update any forward-looking statements. These forward-looking statements are based on MMRGlobal, Inc.’s reasonable expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. The information discussed in this release is subject to various risks and uncertainties related to changes in MMRGlobal, Inc.’s business prospects, results of operations or financial condition, government regulation, and such other risks and uncertainties as detailed from time to time in MMRGlobal, Inc.’s public filings with the U.S. Securities and Exchange Commission.

DENVER, CO and PHOENIX, AZ–(Marketwire – October 8, 2010) –  The Amergence Group (PINKSHEETS: AMNG), a company that focuses on developing, nurturing, and rapidly expanding selected emerging or “disruptive” companies across a wide range of industries and disciplines, announced today that it has completed the successful acquisition of Altitude Organic Licensing Corporation (AO) which is headquartered in Denver, Colorado. Terms for the acquisition will be disclosed in a subsequent release.

The company currently has 5 stores using its Altitude Organic™ Trademark who pay an annual license fee of $15,000 per year. Banding together for strength, the Altitude Organic licensee-dispensaries receive joint-marketing benefits, limited free marketing from corporate, purchasing power on all approved partner products and services, national brand recognition, lobbying efforts, medical marijuana consulting, commercial real estate placement and attorney advisory in addition to booth space at the annual convention.

AO’s prez, Brian Cook, said, “Thanks to the Amergence Group we will now be able to offer a stock compensation plan for all our store owners. I believe this will be a tremendous incentive for prospective dispensary licensees. In addition, our ownership of the National Medical Marijuana Association (NMMA) will put Altitude Organic in ‘pole position’ to provide the best services to our licensees and their customers and enable Altitude Organic to capitalize on this exploding trend. Through this growth process, we must always remain vigilant to defend our high quality standards, developing protocols, and compassionate customer service for our patients.”

Amergence managing director Peter Jacobs stated, “Our acquisition of Altitude Organic Licensing Corp. at this time makes perfect sense for Amergence shareholders. I have been seeing this ‘marijuana legalization wave’ building since 1970 and I sense it is getting ready to crest. The Company’s timing for this acquisition couldn’t be better.”

Altitude Organic Medicine medical marijuana centers are currently located in Denver, CO, Colorado Springs, CO, and San Diego, CA.

The National Medical Marijuana Association (NMMA) commercial can be viewed here: http://www.youtube.com/watch?v=hXQMsPlKJcc

To learn more about the National Medical Marijuana Association visit them here: http://nationalmedicalmarijuanaassociation.org/ 

ABOUT THE AMERGENCE GROUP
The Amergence Group’s (PINKSHEETS: AMNG) provides valuable advice and support to new businesses with its goal of accelerating their intended plans to introduce edgy, disruptive, and/or innovative technologies to the world market. The Company’s 8-year-old Tranzbyte division continues to focus on the development and marketing of its innovative group of optical media enhancement technologies worldwide such as FLASHAlbum, a technology which enables distributors of optic disc media (CDs and DVDs) to combine the best features of both on one USB flash drive.

ABOUT ALTITUDE ORGANIC LICENSING CORPORATION
Altitude Organic Licensing Corporation was founded in Denver during the medical marijuana industry “fever” of early 2010. AO Licensing Corp. generates revenue in the fastest growing industry in the United States without carrying the liability of growing and selling marijuana. The company generates revenue by licensing its “Altitude Organic^™” Federal Trademark to dispensaries. The company also offers medical cannabis advocacy and consulting services to its licensed dispensaries. The corporate website can be found at: www.AltitudeOrganicMedicine.com.

NOTES ABOUT FORWARD-LOOKING STATEMENTS

Except for any historical information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, including those described in the Company’s Securities and Exchange Commission reports and filings. Certain statements contained in this release that are not historical facts constitute forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, and are intended to be covered by the safe harbors created by that Act. Reliance should not be placed on forward-looking statements because they involve unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to differ materially from those expressed or implied. Forward-looking statements may be identified by words such as estimates, anticipates, projects, plans, expects, intends, believes, should and similar expressions and by the context in which they are used. Such statements are based upon current expectations of the Company and speak only as of the date made. The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which they are made.

FLEMINGTON, NJ–(Marketwire – October 8, 2010) –  Ken Glynn, President of SpeechSwitch, Inc. (PINKSHEETS: SSWC), reported today that another of the required SEC documents to bring the company current was submitted today for EDGAR review. The first quarter 2009 Form 10-Q has been completed and submitted to Marketwire for conversion and filing with the U.S. Securities Exchange Commission. This filing will be completed by Marketwire. Additional filings will be made over the next two weeks. The annual report for 2008 (end of year 10-K) will be submitted by the end of next week, as it is still under final attorney review; Second quarter 2009 Form 10Q will be filed within the next week. The company will continue to step up its effort to bring the company current as a pink sheet company as quickly as possible.

Information set forth in this press release contains various “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation reform Act of 1995 (the “Act”) provides certain “safe harbor” provisions for forward-looking statements. The reader is cautioned that such forward-looking statements are based on information available at the time and/or management’s good faith belief with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed statements. Forward-looking statements speak only as of the date the statement was made. We assume no obligation to update forward-looking information to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information. Forward-looking statements are typically identified by the use of terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “should,” “will,” and similar words, although some forward-looking statements are expressed differently. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. 

SAN DIEGO, CA–(Marketwire – October 7, 2010) – Medistem Inc. (PINKSHEETS: MEDS) announced today it has entered into a commercialization agreement with the Indianapolis-based company, General Biotechnology LLC (http://www.gnrlbiotech.com), for sale of its universal donor Endometrial Regenerative Cells (ERC) as a research reagent to qualified academic and corporate institutions. Under the agreement General Biotechnology will harvest menstrual blood from qualified donors, isolate research-grade ERC stem cells, expand and qualify said stem cells and provide a distribution mechanism through its sales network.

“Medistem is a unique company in the area of cellular therapeutics in that its universal donor stem cells have already been used to treat humans,” said Dr. Erik Woods, President and CEO of General Biotechnology LLC. “By making these cells commercially available, scientists around the world will have the ability to compare these cells to existing adult stem cells such as placental, cord blood, and adipose mesenchymal stem cells.”

To date Medistem has reported the use of ERC in treatment of patients with Multiple Sclerosis http://www.translational-medicine.com/content/pdf/1479-5876-7-15.pdf, Duchenne Muscular Dystrophy http://www.ncbi.nlm.nih.gov/pubmed/19917503, and Heart Failure http://www.intarchmed.com/content/pdf/1755-7682-3-5.pdf.

“Since we originally reported the discovery of Endometrial Regenerative Cells in 2007, at least 4 independent groups have used and published on cells with identical or near-identical properties to treat animals with diabetes, Parkinson’s, stroke, and heart failure,” said Dr. Vladimir Bogin, Chairman and President of Medistem. “Given our intellectual property position on these cells, we are confident that by increasing their use in the scientific community we will accelerate our own development efforts, as well as advance the field forward.”

Dr. Michael Murphy, a Harvard-trained vascular surgeon who performs clinical trials using adult stem cells at Indiana University, stated, “The ERC stem cell population represents a treatment for vascular diseases that is novel, highly potent, and easy to integrate into the current standard of care. I am eager to initiate clinical investigations with these cells in treatment of critical limb ischemia.”

Dr. Murphy is the Principle Investigator for an IND filed with the FDA for treatment of critical limb ischemia with Medistem’s ERC stem cells.

About Medistem Inc.

Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company’s lead product, the endometrial regenerative cell (ERC), is a “universal donor” stem cell being developed for critical limb ischemia. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

id=”nav_links”>

EVERETT, WA–(Marketwire – October 7, 2010) –  Fluke Corporation, the global leader in portable electronic test and measurement technology, will send a lucky professional and companion to Arlington, Texas for football’s “Big Game,” simply for learning about the innovative new tools Fluke has recently introduced.

The winner of the Fluke football BIG GAME SWEEPS will receive two tickets to attend the biggest bowl game in football come February 6, 2011. The sweepstakes package includes airfare, three nights of lodging, and a complimentary rental car. The winner will be selected by random drawing and announced the first week of January 2011.

The Fluke football BIG GAME SWEEPS marks the start of an exciting season for Fluke customers. Fluke has just announced a new family of innovative, high-performance clamp meters. Other recent introductions include the groundbreaking Fluke 233 Remote Display Multimeter, the first of its kind in the industry; the Fluke 28 II Industrial Multimeter for ultra rugged conditions; and the Fluke Ti32 Thermal Imager with a powerful 320 x 240 sensor. 

To enter the Fluke football BIG GAME SWEEPS, customers simply choose a featured product online at www.fluke.com/footballsweeps, read a short description and then complete a registration form for a chance to win. Contestants are limited to one entry per person. No purchase is required.

Participation in the Fluke football BIG GAME SWEEPS is limited to licensed contractors or individuals in a professional trade who are residents of the U.S. and age 21 or older.

Sweepstakes ends December 31, 2010. See official rules at www.Fluke.com/footballsweeps.

For More Information

Fluke test instruments are distributed in more than 100 countries. For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail [email protected] or visit the Fluke Web site at http://www.fluke.com.

Follow Fluke on Facebook, Twitter, YouTube or Linkedin.

About Fluke

Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools. Fluke tools deliver the testing and troubleshooting capabilities that are critical to keep commerce and industry running smoothly. Fluke customers are technicians, engineers, electricians, metrologists and building diagnostic professionals who install, troubleshoot and manage industrial, electrical and electronic equipment and calibration processes for quality control and building restoration. In the past five years, Fluke tools won more than 50 industry awards, including Test and Measurement World Best in Test, Control Engineering Engineer’s Choice, and Plant Engineering Product of the Year. Fluke is a registered trademark of Fluke Corporation in the United States and/or other countries. The names of actual companies and products mentioned herein may be the trademarks of their respective owners.

EVERETT, WA–(Marketwire – October 7, 2010) – Fluke Corporation, the global leader in portable electronic test and measurement technology, has introduced new iFlex^™ flexible current probes, designed to make current measurement easier, more convenient and more precise for electricians and industrial technicians.

The new Fluke iFlex flexible current probes expand the measurement range of select Fluke meters to 2500 A ac and give technicians the ultimate in measurement flexibility. The large coil allows users to reach around large or awkward-shaped conductors up to 6 inches in diameter, while the small 0.3-inch profile allows the coil to reach between tightly-packed cables and improves access in crowded spaces. A 6-foot cord makes it easier to see readings at a distance from the conductor.

The iFlex probes connect directly to the meter, displaying current measurements without error-prone scaling factors. In addition to ac current measurement, they also work with frequency, inrush, and min/max/avg functions. The iFlex current probes are available in 10-inch and 18-inch sizes.

The iFlex current probe i2500-18 is included with the new Fluke 381 and Fluke 376 Clamp Meters. Both iFlex models — the i2500-18 and the i2500-10 — are compatible with Fluke 374 and Fluke 375 Clamp Meters. US list price for each iFlex probe model is $98.95.

The iFlex current probes are members of a new family of Fluke clamp meters designed to meet users’ requirements for flexibility, safety and performance in the most challenging industrial conditions. This new Fluke family of clamp meters includes:

Fluke 381 Remote Display True-rms AC/DC Clamp Meter with iFlex — The Fluke 381 is a full-featured clamp meter with an important extra: Users can remove the detachable wireless display for even more flexibility, convenience and safety. Now one technician can do jobs that used to require two. US list price is $498.95.

Fluke 376 True-rms AC/DC Clamp Meter with iFlex — With the new Fluke 376 Clamp Meter, users will be ready for any measurement challenge. Designed for the toughest industrial environments, it measures current up to 2500 A ac and 1000 A dc and can troubleshoot even the noisiest motors and drives. US list price is $374.95.

Fluke 374 and 375 True-rms AC/DC Clamp Meters — The new Fluke 374 and 375 clamp meters offer improved performance, perfect for many current measurement situations. With true-rms ac voltage and current measurements, the Fluke 374 and 375 can read up to 600 V and 600 A in both ac and dc modes and handle min/max, average and inrush recording. Both are compatible with the new iFlex flexible current probe (sold separately). US list price for the Fluke 375 is $299.95, for the Fluke 374, $259.95.

Fluke 373 True-rms AC Clamp Meter — The new Fluke 373 clamp meter offers improved performance and maximum value for users requiring ac only current measurement. US list price is $179.95.

The Fluke 381, 376, 375, 374 and iFlex current probes are rated for safe use in hazard category IV (CAT IV) 600V environments (CAT IV 600V, CAT III 1000 V) as defined by safety regulators in the US, Canada and Europe. The Fluke 373 is rated CAT IV 300V, CAT III 600V. Category IV environments include overhead power lines, underground power lines and service entrance power, as well as all outdoor environments.

For More Information

Fluke test instruments are distributed in more than 100 countries. For more information on the entire new Fluke clamp line, go to www.fluke.com/ReadyForAnything. For more information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail [email protected] or visit the Fluke Web site at http://www.fluke.com.

Follow Fluke on Facebook, Twitter, YouTube or Linkedin.

About Fluke

Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools. Fluke tools deliver the testing and troubleshooting capabilities that are critical to keep commerce and industry running smoothly. Fluke customers are technicians, engineers, electricians, metrologists and building diagnostic professionals who install, troubleshoot and manage industrial, electrical and electronic equipment and calibration processes for quality control and building restoration. In the past five years, Fluke tools won more than 50 industry awards, including Test and Measurement World Best in Test, Control Engineering Engineer’s Choice and Plant Engineering Product of the Year. Fluke is a registered trademark of Fluke Corporation in the United States and/or other countries. The names of actual companies and products mentioned herein may be the trademarks of their respective owners.

CHARLOTTE, NC–(Marketwire – October 6, 2010) – Patient Care Technology Systems (PCTS), a subsidiary of Consulier Engineering, Inc. (NASDAQ: CSLR) today announced they have signed a record number of contracts for the year and that 100% of their existing tracking customers have renewed their agreements for ongoing solutions and services.

“There is no stronger endorsement of our company and solutions than the dramatic increase in new contract signings and the continual renewal, and expansion of customer agreements. Every year, our customers almost unanimously renew their agreements. They expand their implementations while finding greater value in our breadth of solutions,” said Tony Marsico, PCTS president and CEO.

Renewals are executed when customers want to extend their agreement with PCTS to provide additional products, maintenance and/or support. So, the 100% renewal rate means that every customer who was with PCTS in January of 2010 will continue their agreements in 2011.

“The renewal of these agreements is extremely important as they not only provide a viable, ongoing stream of revenue that supports enhanced research and development, but also because they provide validation that the company as a whole is approaching the market with the right innovative solutions that are clearly in demand. The benefits of these solutions more than justify the investment the health care organizations are making in PCTS. The financial and performance advantages we offer our clients are what’s driving the accelerating growth we are seeing,” says Warren Mosler, CEO of Consulier Engineering, the primary shareholder of PCTS.

“What is equally exciting, is that almost every customer doesn’t just renew their existing agreement, but actually comes back to us for additional work each year,” states Jaime Ojeda, PCTS vice president of sales and business development. Ojeda says, “In 2010 alone, we will have about 70% of our existing tracking customers expand their PCTS installations. This, combined with the record number of sales we have made to new customers, is what is driving our continued growth and validates PCTS as the ‘go to’ provider of healthcare real time locating and workflow automation systems. PCTS has been supporting the healthcare industry since 1997 and our exceptional growth will allow us to expand our offerings.”

To facilitate and manage this growth, so far in 2010, PCTS has increased employment by almost 20% and is estimating almost double that in 2011.

“That we have been able to increase revenues as much as we have with only a 20% increase in staff is also very encouraging,” says Tony Marsico. “The work we have done to deliver our solutions in as efficient a way as possible is allowing us to enjoy the tremendous growth without excessive increases in overhead or any need to increase prices.”

In February of this year, the company announced the opening of a subsidiary based outside of London that will service the UK and European Union. Patient Care Technology Systems, Ltd. is holding two seminars the week of October 11 that will present innovative techniques for improving accident and emergency department (A&E) productivity, streamlining workflow, and improving overall operational efficiency and quality of practice.

Tony Marsico adds, “Since becoming CEO in April 2005, my emphasis, and hence our company’s emphasis, has been ensuring that our customers realize the complete value of our solutions. This includes much more than just customer service. We are automating hospital workflow through visibility, communication and real-time tracking of interactions between entities, patients and staff. This has successfully allowed our customers to consistently enhance revenue and contain costs, resulting in solid, bottom-line returns on their investment. Our renewal rate shows that they are getting that ROI and our focus is paying off.”

About Patient Care Technology Systems

Patient Care Technology Systems, a subsidiary of Consulier Engineering, Inc. (NASDAQ: CSLR), helps health care providers to improve patient flow, increase capacity and improve patient and staff safety by visualizing the real time location and status of people and equipment throughout their facility. PCTS solutions have supported over 2 million patient visits annually and have shown a proven return on investment in high turnover, high-acuity units such as the emergency department and perioperative suites. The Amelior Enterprise Visibility and Workflow Automation Suite™ is interoperable with all leading locating technologies, including active-RFID, infrared, ultrasound, ultra-wideband, Wi-Fi and ZigBee. PCTS customers have been recognized nationally for improvements in efficiency and clinical excellence. For more information, visit www.pcts.com and connect to PCTS on Facebook and Twitter.

This press release contains forward-looking statements within the meaning of federal securities laws. PCTS and CSLR caution you that any statements contained in this press release which are not strictly historical statements constitute forward-looking statements. Such forward-looking statements include, but are not limited to, those related to PCTS’s and CSLR’s expectations regarding continued business growth. These statements are neither promises nor guarantees, and involve risks and uncertainties that could cause actual results to differ materially from such forward-looking statements, (copies of which may be obtained at the SEC’s website at: http://www.sec.gov) — could impact the forward-looking statements contained in this press release. Readers should not place undue reliance on any such forward-looking statements, which speak only as of the date they are made. PCTS and CSLR disclaim any obligation to publicly update or revise any such statements to reflect any change in PCTS and CSLR’s expectations, or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Click here to see all recent news from this company

VICTORIA, BRITISH COLUMBIA–(Marketwire – Oct. 6, 2010) – Vigil Health Solutions Inc. (“Vigil”) (TSX VENTURE:VGL) is pleased to announce its selection as one of the fastest-growing companies in B.C. by Business In Vancouver newspaper. Vigil, and other award recipients, were honoured at the Top 100 Fastest Growing Companies reception held last night in Vancouver. Vigil was ranked 40th among 100 of the fastest growing companies in B.C. based on revenue growth for the five-year period between fiscal 2005 and 2009.

About Vigil Health Solutions Inc.

Vigil offers a proprietary technology platform combining software and hardware to provide comprehensive solutions to the expanding seniors’ housing market. Vigil has established a growing presence in North America and an international reputation for being on the leading edge of systems design and integration. The Vigil Integrated Care Management System™ (Vigil® System) includes the award-winning Vigil Dementia System, a nurse call system, bed monitoring, resident check in, and the latest development the Vigil Wireless call system. The first to supply dementia specific care technology, Vigil facilitates the highest standard of care for cognitive residents while helping dementia residents enjoy a higher quality of life and greater dignity.

PHILADELPHIA, PA–(Marketwire – October 6, 2010) –  There is much focus on patient recruitment, specifically finding patients willing to participate in clinical trials. However, the second phase of recruitment is often overlooked: pulling prospective patients through the referral pipeline and into the study center. This phase occurs after patients pass a pre-screener that matches them to the study’s criteria. It is during this phase that pre-screened patients wait for site follow-up that often does not occur.

To streamline the recruitment ‘pull-through’ process and increase recruitment success, MediciGlobal introduces the Study Resource Center™ and welcomes Pat Patterson, RN, CCRC as its Director. Pat is a certified clinical research nurse with nearly 20 years of clinical research experience at academic, hospital and community based research settings. Pat has seen first-hand the need for a central resource providing sites with services that save time on processing patient referrals.

MediciGlobal established the Study Resource Center in response to growing numbers of requests from study coordinators and site marketing managers to directly provide services that support finding patients, pulling those patients most likely to randomize through the referral pipeline, and retaining patients long term.

The Study Resource Center is a place for sites to go when they need recruitment-retention support. Pat contends that study coordinators like to know they are dealing with someone who understands their issues. MediciGlobal has supported sites indirectly through study sponsors, but now these services can be accessed directly by sites, and include:

1. Education: building effective recruitment-retention programs
2. Efficient pre-screening
3. Logistical support: appointment scheduling, patient follow up
4. Problem solving: innovative recruitment approaches. 
5. Advertising and eMarketing support
6. Retention: during and post active treatment
7. Lost-to-follow up: Find missing patients

The Study Resource Center integrates MediciGlobal’s Site Support team with the services of its in-house patient contact center, ProtoCall^®. Centralizing these functions enhances the coordination of critical recruitment-retention support services to study sites.

Ms. Patterson was one of the first to undergo the Association of Clinical Research Professionals’ (ACRP’s) qualification process for a certified clinical research coordinator (CCRC). Recognized as a consistent performer for studies conducted for major biopharmaceutical sponsors, Pat served on numerous national and international study advisory boards.

About MediciGlobal
MediciGlobal based in the U.S. and U.K., is a specialty patient recruitment — retention company, developing programs for clinical trials of all sizes in countries around the globe. www.mediciglobal.com

DUBAI, UNITED ARAB EMIRATES–(Marketwire – Oct. 6, 2010) – The recent re-launch of a global networking web-site has attracted thousands of healthcare industry affiliated professionals keen to share information on-line. The website, www.GlobalHealthcareNetwork.com was revamped last month to help facilitate (showcase/broadcast) research, provide business & networking opportunities and act as an easily accessible forum for healthcare issues and challenges (around the world to be discussed) The site is also proving popular as an informal tool that allows members to socialise with their healthcare peers in other countries.

“This is the age of social networking and a great deal of information is now being traded (exchanged) on-line using this method,” said Dr. Prem Jagyasi, renowned global healthcare consultant and founder of the Global Healthcare Network. “There are many general purpose social networking sites with millions of users, but we were encouraged by healthcare professionals across the world to create a site designed especially with the sector in mind,” he added.

The www.GlobalHealthcareNetwork.com is unique in that it has customised settings so that healthcare professionals can participate in specific activities. Healthcare professionals using the site can join various special interest groups in the sector; such as Healthcare Management, Healthcare Marketing, Healthcare Insurance, Pharmaceutical, Medical Equipment, Healthcare Finance, Healthcare Journalist and, Medical Tourism (Health Tourism / Healthcare Travel / Medical Travel), amongst others.

The site also aggregates the latest news from around the world to provide easy access of vital healthcare information at one place, as well as offering all the standard networking benefits that include connections, blogging, forum discussions, media uploads and event updates. The network is integrated with Facebook and Twitter so members can post to other networking sites from Global Healthcare Network. The Global Healthcare Network also has group/fan pages on LinkedIn, Facebook and Twitter, with more than 1750 members actively communicating.

Dr. Jagyasi believes that the advantage of the Global Healthcare Network is that it allows for health professionals to share information easily, which in turn breaks down barriers and improves cooperation between healthcare providers. “Even the small links that are established through purely social interaction can develop into bigger links over time, as channels of communication become progressively embedded,” he said. “We can see from the buzz and chatter happening on the site that connections are being made that should lead to the forging of relationships that can only benefit healthcare in the future. I believe that this site will act as an important adjunct to the continued growth of the sector worldwide,” he added. 

The site provides us with updated information about all upcoming healthcare events worldwide at one place.

Dr Prem Jagyasi, recently presented the topic ‘ Social Media Marketing’ at the World Medical Tourism and Global Healthcare Association 2010 in Los Angeles, USA. The presentation provided a prescriptive roadmap for Online Media and Social Media Success while discussing best practices and answering the biggest questions faced by health care marketers in the field of Social Media Marketing. His presentation is also available to view on www.slideshare.net/jagprem or www.GlobalHealthcareNetwork.com or www.DrPrem.com.

Anyone, health professional or otherwise, can access the Global Healthcare Network by logging on to http://www.globalhealthcarenetwork.com and creating a user account. They will then be able to connect to health workers from around the world.

Below are quick links:

Global Healthcare Network Site: www.GlobalHealthcareNetwork.com

Members: http://www.globalhealthcarenetwork.com/profiles/members/

Notes & News http://www.globalhealthcarenetwork.com/notes/index/allNotes

Forums http://www.globalhealthcarenetwork.com/forum

Blogs http://www.globalhealthcarenetwork.com/profiles/blog/list

Facebook Page http://www.facebook.com/pages/Global-Healthcare-Medical-Tourism-Health-Tourism/105868006128124

LinkedIn http://www.linkedin.com/groups?mostPopular=&gid=2997546

Twitter http://twitter.com/Globalhcn

About Global Healthcare Network

Global Healthcare Network is a unique social networking platform for Healthcare Professionals. Join the group now to Network, share & learn. There is a total of 1750+ Network members across all Global Healthcare Networking sites/pages including facebook & linkedin.

The network allows you to create blog, start discussion, join various healthcare groups, promote your services.

About Dr Prem Jagyasi

A successful entrepreneur and experienced strategic professional, Dr Prem Jagyasi is a renowned Chartered Management, Healthcare Marketing and Medical Tourism Consultant. Providing high-profile consultancy services to Government authorities and private healthcare organizations, Dr. Prem Jagyasi is a noticeably leading Global Healthcare and medical tourism consultant in the world.

Apart from running a successful healthcare solution firm and consultancy business, he has initiated several innovative healthcare awareness projects such as Family Health Festival, No Tobacco Campaign, Summer Health Festival, Ahlan Ramadan and Diabetes Events. His initiatives are endorsed and recognized by the country’s ministry of health and other government authorities. On a global front, he is also working on Medical Tourism Guide, Educational Events, Global Health Directory, and workshops on quality practice for international patients. etc.

Currently, Dr Prem Jagyasi is MD & CEO of ExHealth, a Dubai HealthCare City based firm engaged in offering multi-dimensional healthcare solutions in international domain. He also serves the Medical Tourism Association (also known as Global Healthcare Association) —a Non Profit organization based in USA as Honorary Chief Strategy Officer. He is also the Chief Editor of UAE’s leading health magazine – HealthFirst, published in association with one of the leading English dailies of the region.

LOS ANGELES, CA–(Marketwire – October 6, 2010) –  MMRGlobal, Inc. (OTCBB: MMRF) (MMR) announced today that its MMR Stimulus Program will be expanded to include the MMRPro Insurance Advance Program. This program is an expansion of the existing MMRPro Stimulus Program launched in the first quarter of 2010 which rewards MMRPro users when their patients upgrade to the MyMedicalRecords Personal Health Record. 

The Insurance Advance Program is designed to help MMRPro healthcare professionals smooth out cash flow during their transition to achieving meaningful use. MMRPro users will be paid advances on the uncollected commercial third-party amounts they billed each preceding week to the extent permitted by federal and state laws and regulations. They must use an MMRGlobal approved Stage 1-Certified Meaningful Use practice management and billing system to be eligible to receive payments under the MMRPro Stimulus Insurance Advance Program. The program will be part of the Company’s previously announced plans to offer one or more EMR products, which could include applications for iPad and PC-based platforms in addition to its MMRPro and MyMedicalRecords Personal Health Record products. 

“We recognize that converting an existing billing system to one that enables the practice to achieve meaningful use could affect a practice’s cash flow, which could also affect the lifeblood of the practice,” said Robert H. Lorsch, Chairman and CEO of MMRGlobal. “One of the largest problems doctors and hospitals face today is reimbursement for their services. Our goal is to assist doctors, hospitals and medical groups in maintaining control of their finances while transitioning to meaningful use at the same time healthcare reform is being implemented.”

Additionally, MMRPro users and their patients continue to receive protection under MMRGlobal’s million dollar Cyber Liability Insurance Policy, which, among other things, protects healthcare professionals using MMRPro defend themselves in the event of a violation of the expanded HIPAA regulations under the Health Information Technology for Economic and Clinical Health Act (HITECH). 

The underlying Cyber Liability policy is underwritten by an A-rated insurance company by A.M. Best to cover damages arising from the use and deployment of the Company’s personal and professional health record products and services. The coverage extends to MMRGlobal’s corporate clients that offer MMR’s products and services as an employee benefit and to individuals who sign up to receive MMR’s services over the Internet.

About MMRGlobal, Inc.

MMR Global, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMR Global, Inc. and its products, visit www.mmrglobal.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as “need,” “possibility,” “offer,” “development,” “if,” “negotiate,” “when,” “begun,” “believe,” “achieve,” “help,” “will,” “estimate,” “expect,” “maintain,” “plan,” and “continue,” or the negative of these words. Factors that could cause or contribute to such differences include, but are not limited to, the risk the Company’s products and programs are not adopted or viewed favorably by the healthcare community; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; variations in our quarterly operating results; timing and volume of sales and installations; length of sales cycles and the installation process; market acceptance of new product and program introductions; ability to establish and maintain strategic relationships; ability to identify and integrate acquisitions; relationships with licensees; competitive product offerings and promotions; changes in government laws and regulations and future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; acceptance of the Company’s marketing and promotional campaigns; risks related to a security breach by third parties; maintaining, developing and defending our intellectual property rights including those pertaining to our biotechnology assets; risks associated with recruitment and retention of key personnel; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company’s filings with the Securities and Exchange Commission. Additionally, we are a developing early-stage company and many variables can affect revenues and/or projections, including factors out of our control. The Company is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Click here to see all recent news from this company

BOCA RATON, FL–(Marketwire – October 6, 2010) – David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Vicor has selected Dell’s Healthcare and Life Sciences division to serve as its worldwide hardware partner for the Company’s PD2i Analyzer™ and PD2i CA™ (Cardiac Analyzer). According to the terms of the agreement, Dell will create Vicor-labeled laptop computers specifically customized to Vicor’s specifications and package them for Vicor’s worldwide distribution. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i^® nonlinear algorithm and software. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i^® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that accurately risk stratify specific target populations for future pathological events, including congestive heart failure patients for cardiac death resulting from arrhythmia or pump failure, diabetics for diabetic autonomic neuropathy (DAN), and trauma victims for imminent death absent immediate lifesaving intervention.

“Dell Healthcare and Life Sciences is proud to be chosen as Vicor’s worldwide IT solutions provider. Dell is committed to developing and supporting healthcare IT solutions to improve care and delivery,” stated Scott Jenkins, PhD, Vice President, Dell, Inc.

 “We’re thrilled to have Dell as our worldwide IT solutions partner. Dell’s well-established reputation for creating innovative technologies and business solutions, strong internal development capabilities, global reach, and consumer-centric approach make it the perfect worldwide IT solutions partner for Vicor,” stated Mr. Fater. 

“Given the growing amount of positive feedback we’re receiving from physicians and cardiologists using the PD2i Analyzer™ to enhance diagnosis of those at risk of cardiac death from arrhythmia or pump failure, as well as autonomic neuropathy, we’re extremely optimistic about the prospects for the PD2i Analyzer™ and PD2i CA™ worldwide. These diagnostics have enabled the physicians and cardiologists using them to use existing CPT codes for reimbursement, strengthened their ability to diagnose difficult to identify conditions, and enabled early, sometimes life-saving treatment,” Mr. Fater concluded.

About Vicor Technologies, Inc.
Vicor Technologies is focused on commercializing innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i^®). The PD2i^® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability. Physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in various clinical trials, identifies patients at elevated risk of cardiac death resulting from arrhythmia or pump failure.

Vicor anticipates developing additional applications utilizing the PD2i^® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

Disclaimer
The appearance in this release of name-brand institutions, such as Dell and the U.S. Army Institute for Surgical Research, does not constitute endorsement by these institutions of the information, products, or services contained therein.

Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain FDA approval of our 510(k) submission to secure a marketing claim for the PD2i CA™(Cardiac Analyzer) for testing patients for cardiovascular disease and our ability to obtain marketing clearance from the FDA for the PD2i VS™ (Vital Sign) for military and civilian applications; our ability to obtain the necessary regulatory approvals to market in the People’s Republic of China; our ability to develop additional applications for the PD2i^®algorithm; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to successfully complete the normal range study for PD2i^®values; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 10-18

Click here to see all recent news from this company